SAR441344 IV

DRUG2 trials

Sponsors

Sanofi

Conditions

Multiple SclerosisSystemic Lupus Erythematosus

Phase 2

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Active, not recruitingNCT04879628

SanofiMultiple Sclerosis

Start: 2021-06-07End: 2027-08-23Updated: 2025-09-30

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Active, not recruitingNCT05039840

SanofiSystemic Lupus Erythematosus

Start: 2021-11-10End: 2026-10-02Updated: 2026-03-27

Related Papers

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)

Neurology2024-04-09

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

New England Journal of Medicine2024-02-1464 citations